- Home
- RIGL vs MREO Comparison
RIGL vs MREO Comparison
Compare RIGL & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- MREO
- Stock Information
- Founded
- RIGL 1996
- MREO 2015
- Country
- RIGL United States
- MREO United Kingdom
- Employees
- RIGL N/A
- MREO N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- RIGL Health Care
- MREO Health Care
- Exchange
- RIGL Nasdaq
- MREO Nasdaq
- Market Cap
- RIGL 366.5M
- MREO 369.2M
- IPO Year
- RIGL 2000
- MREO N/A
- Fundamental
- Price
- RIGL $17.17
- MREO $2.16
- Analyst Decision
- RIGL Buy
- MREO Strong Buy
- Analyst Count
- RIGL 5
- MREO 7
- Target Price
- RIGL $36.80
- MREO $7.71
- AVG Volume (30 Days)
- RIGL 253.6K
- MREO 1.2M
- Earning Date
- RIGL 03-04-2025
- MREO 03-26-2025
- Dividend Yield
- RIGL N/A
- MREO N/A
- EPS Growth
- RIGL N/A
- MREO N/A
- EPS
- RIGL 0.99
- MREO N/A
- Revenue
- RIGL $179,278,000.00
- MREO N/A
- Revenue This Year
- RIGL $14.19
- MREO N/A
- Revenue Next Year
- RIGL $13.10
- MREO $69.09
- P/E Ratio
- RIGL $17.17
- MREO N/A
- Revenue Growth
- RIGL 54.71
- MREO N/A
- 52 Week Low
- RIGL $7.48
- MREO $2.11
- 52 Week High
- RIGL $29.82
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- RIGL 34.02
- MREO 34.50
- Support Level
- RIGL $17.01
- MREO $2.16
- Resistance Level
- RIGL $19.97
- MREO $2.73
- Average True Range (ATR)
- RIGL 1.01
- MREO 0.14
- MACD
- RIGL -0.29
- MREO -0.01
- Stochastic Oscillator
- RIGL 10.65
- MREO 14.91
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).